ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat

Therapy resistance is a major clinical problem in cancer medicine and crucial for disease relapse and progression. Therefore, the clinical need to overcome it, particularly for aggressive tumors such as pancreatic cancer, is very high. Aberrant activation of an epithelial–mesenchymal transition (EMT...

Descripción completa

Detalles Bibliográficos
Autores principales: Meidhof, Simone, Brabletz, Simone, Lehmann, Waltraut, Preca, Bogdan-Tiberius, Mock, Kerstin, Ruh, Manuel, Schüler, Julia, Berthold, Maria, Weber, Anika, Burk, Ulrike, Lübbert, Michael, Puhr, Martin, Culig, Zoran, Wellner, Ulrich, Keck, Tobias, Bronsert, Peter, Küsters, Simon, Hopt, Ulrich T, Stemmler, Marc P, Brabletz, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459821/
https://www.ncbi.nlm.nih.gov/pubmed/25872941
http://dx.doi.org/10.15252/emmm.201404396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459821/
https://www.ncbi.nlm.nih.gov/pubmed/25872941
http://dx.doi.org/10.15252/emmm.201404396

Ejemplares similares